Mark Beaudet is a co-founder of Paladin Labs Inc., a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products, that was acquired by Endo International plc in 2014 for approximately $3.0 billion. Since Paladin’s founding in 1996, Mr. Beaudet served as a member of the board of directors and as the company’s Vice President of Sales and Marketing until 2011 when he became interim President and CEO. Following Endo’s acquisition of Paladin, Mr. Beaudet joined the Endo International plc. executive leadership team and continued to lead the Paladin team until his departure in June 2016. Prior to his work with Paladin, Mr. Beaudet held marketing management positions at Procter & Gamble Canada and Pizza Hut Canada. Mr. Beaudet is a member of the board of directors of the McGill University Health Center Foundation, Loyola High School and the Loyola High School Foundation. Mr. Beaudet also serves on the board of Altus Formulations Inc., a privately held drug formulation and development company. He is a former member of the board and former Chair of the Regulatory Affairs Committee of Innovative Medicines Canada (formerly Rx&D - Canada’s Research Based Pharmaceutical Industry Association). Mr. Beaudet holds a B.Comm in Marketing and Entrepreneurship from McGill University and is recognized as a Certified Market Research Professional (CMRP) by the Canadian Market Research and Intelligence Association and as an Accredited Pharmaceutical Manufacturer’s Representative by the Council for Continuing Pharmaceutical Education (CCPE). In 2003 Mr. Beaudet was a co-recipient of the Ernst and Young Entrepreneur of the Year award in the Quebec Life Sciences Sector. In 2015 Mr. Beaudet was inducted into the Canadian Healthcare Marketing Hall of Fame.